Is Egrifta (Tesamorelin) Legal in Maryland?

The Federal Legal Foundation for Tesamorelin

Tesamorelin carries full FDA approval. That single fact places it in a completely different legal category from research-grade peptides like CJC-1295 or ipamorelin.

The FDA granted approval of Egrifta (tesamorelin 1 mg) on November 10, 2010, under NDA 022505, for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A reformulated 2 mg product branded Egrifta SV received subsequent approval. Because the drug went through the full NDA pathway, it is subject to standard prescription-drug rules under the Federal Food, Drug, and Cosmetic Act (FD&C Act) rather than the more ambiguous framework that governs unapproved peptides. [1]

Why "FDA Approved" Matters for Legal Access

An FDA-approved drug is dispensed legally to any patient with a valid prescription for its approved indication, or for an off-label use at a licensed prescriber's clinical judgment. Tesamorelin is not listed as a controlled substance under the Controlled Substances Act, meaning it does not require a DEA-issued Schedule II or III prescription and is not tracked through Maryland's prescription-drug monitoring program (PDMP) the way opioids are. [2]

Contrast this with peptides that appear on the FDA's list of bulk drug substances that may not be used in compounding. Tesamorelin does not appear on the FDA's "Bulks 2" negative list, which is the list of substances nominated for, but refused, inclusion as permissible compounding ingredients. That absence matters when evaluating compounding pharmacy access, discussed below.

Comparing Tesamorelin to Other Peptides

| Peptide | FDA Status | Compounding Allowed | MD Schedule | |---|---|---|---| | Tesamorelin (Egrifta SV) | Approved (NDA 022505) | 503A: yes, individual Rx | Not scheduled | | Semaglutide | Approved (Ozempic/Wegovy) | 503A/503B: drug shortage only | Not scheduled | | CJC-1295 | Not approved | Prohibited (on bulks negative list) | Not scheduled | | Ipamorelin | Not approved | Prohibited (on bulks negative list) | Not scheduled | | Sermorelin | Not approved; withdrawn | 503A: allowable as bulk substance | Not scheduled |

This table illustrates why tesamorelin occupies a favorable position. Patients and prescribers are not navigating a gray area. [3]

Maryland State Law and Tesamorelin

Maryland does not impose any state-specific restrictions on tesamorelin beyond the federal baseline. No Maryland statute schedules it as a controlled dangerous substance (CDS) under the Maryland Controlled Dangerous Substances Act (Criminal Law Article, Title 5). The Maryland Medical Practice Act (Health Occupations Article, Title 14) simply requires that any prescription drug be ordered by a licensed practitioner acting within a valid patient-provider relationship. [4]

The Maryland Board of Pharmacy

The Maryland Board of Pharmacy regulates both retail pharmacies and compounding facilities operating in the state. Any pharmacy dispensing Egrifta SV must hold a valid Maryland pharmacy permit. Compounding pharmacies operating as 503A facilities must comply with USP Chapter 797 sterile compounding standards and dispense only pursuant to individual patient prescriptions. The Board does not maintain a separate restricted list for tesamorelin. [5]

Maryland's Telehealth Laws

Maryland adopted telehealth-friendly regulations that allow prescribers to evaluate patients via synchronous audio-video platforms and issue valid prescriptions, including for injectable medications, provided a legitimate patient-provider relationship exists. The Maryland Health Care Commission and the Board of Physicians both permit this model. This means a Maryland resident can receive a tesamorelin prescription after a video consultation without an in-person visit, as long as the prescriber meets standard-of-care documentation requirements. [6]

Who Can Legally Prescribe Tesamorelin in Maryland

Any Maryland-licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) operating within their scope of practice can prescribe tesamorelin. Endocrinologists and infectious disease specialists write most tesamorelin prescriptions because the approved indication sits within those specialties. Practitioners focused on metabolic medicine and age-management medicine also prescribe it off-label.

On-Label vs. Off-Label Prescribing

The FDA-approved indication is narrow: reduction of excess abdominal fat (lipohypertrophy) in HIV-positive adults. Off-label prescribing is legal under U.S. Law and is common in clinical practice. The American Association of Clinical Endocrinology does not currently list tesamorelin in its 2023 obesity management guidelines, but off-label use for growth hormone deficiency (GHD) assessment and body-composition support has been described in the literature. [7]

Off-label prescribing does carry implications for insurance coverage and places the clinical justification burden on the prescriber. Patients pursuing tesamorelin for non-HIV indications should expect to document the clinical rationale thoroughly.

What a Valid Prescription Requires

Maryland follows federal requirements for a valid prescription: the prescriber's name, address, DEA number (if applicable), patient's name and address, date, drug name and strength, quantity, directions for use, and refills authorized. Because tesamorelin is not a controlled substance, the DEA number is not legally required on the prescription form, though many pharmacies request it as a verification step.

How to Get Egrifta (Tesamorelin) in Maryland: Four Legal Pathways

Pathway 1: Brand-Name Egrifta SV Through a Retail or Specialty Pharmacy

Theratechnologies manufactures Egrifta SV (2 mg/vial). Patients with a valid prescription can fill it at specialty pharmacies that handle injectables, including national chains with specialty divisions and independent specialty pharmacies licensed in Maryland. The list price runs high (roughly $4,000 to $6,000 per month for the brand), so most patients pursue insurance coverage or manufacturer patient-assistance programs.

For HIV-positive patients with qualifying lipodystrophy, many Medicaid plans covering Maryland residents include Egrifta SV on formulary with prior authorization. Maryland Medicaid (HealthChoice) follows federal Medicaid rules, which require coverage of medically necessary FDA-approved drugs. [8]

Pathway 2: 503A Compounding Pharmacy

A 503A compounding pharmacy can prepare a tesamorelin formulation for a specific patient when a licensed prescriber writes an individualized prescription. Because tesamorelin is an FDA-approved drug substance, a 503A pharmacy compounds it under the FD&C Act's Section 503A provisions, which permit compounding of approved drugs when there is a specific patient need that the commercially available product does not meet (for example, a patient requiring a different concentration or diluent).

Critically, tesamorelin is NOT on the FDA's list of bulk drug substances that may NOT be used in compounding (the so-called "negative list"). This means 503A compounding of tesamorelin remains permissible, subject to the pharmacy obtaining the active pharmaceutical ingredient (API) from an FDA-registered supplier and complying with USP 797 sterile standards. Cost through a 503A compounder typically runs $150 to $400 per month, depending on dose and formulation. [9]

Pathway 3: Telehealth Prescribers Operating in Maryland

Several telehealth platforms are licensed to practice in Maryland and can connect patients with prescribers who evaluate metabolic or endocrine concerns. After a clinical intake, lab review, and synchronous video consultation, a Maryland-licensed clinician can issue a tesamorelin prescription that the patient fills at a partnered 503A pharmacy. This pathway is fully legal under Maryland telehealth rules, provided the platform and its prescribers hold Maryland licensure. [6]

Patients should verify:

• The prescriber holds an active Maryland license (searchable at the Maryland Board of Physicians website).
• The compounding pharmacy holds a Maryland pharmacy permit or is licensed as an out-of-state pharmacy shipping into Maryland.
• The platform does not dispense without a genuine clinical evaluation.

Pathway 4: In-Person Specialist Consultation

Patients in Baltimore, Bethesda, Rockville, Annapolis, or other Maryland metro areas can book with an endocrinologist or infectious disease specialist directly. Academic medical centers including Johns Hopkins Hospital and University of Maryland Medical Center have established endocrinology departments equipped to evaluate GH-related conditions. A specialist visit often involves baseline IGF-1 testing, fasting glucose, and metabolic panels before initiating tesamorelin.

Clinical Evidence Supporting Tesamorelin

Understanding what the clinical data actually show helps both patients and prescribers make informed decisions.

Phase 3 Trial Data

The key registration trials enrolled HIV-positive adults with abdominal lipohypertrophy. Falutz et al. (2007, N=412) published in the New England Journal of Medicine demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 15.2% vs. 1.7% placebo (P<0.001) at 26 weeks. [10] A 52-week extension showed sustained VAT reduction with continued therapy.

Dhillon (2011) reviewed the pharmacology and clinical data supporting the NDA and confirmed that tesamorelin's selectivity for the pituitary GHRH receptor results in physiologic, pulsatile GH release rather than the supraphysiologic levels associated with exogenous GH administration. This profile translates to a lower incidence of edema, arthralgia, and carpal tunnel syndrome compared with direct GH therapy. [11]

Safety Considerations Prescribers Monitor

Tesamorelin can raise fasting glucose and IGF-1 levels. The FDA label specifies monitoring for glucose intolerance and diabetes. The drug is contraindicated in patients with active malignancy, during pregnancy, and in those with disruption of the hypothalamic-pituitary axis caused by hypophysectomy, hypopituitarism, or pituitary tumor. [1]

Maryland prescribers following standard of care order IGF-1 and fasting glucose at baseline and at 3-month intervals during therapy. If IGF-1 rises above the age-adjusted normal range, dose reduction or discontinuation is considered.

What Disqualifies a Tesamorelin Source in Maryland

Not every online vendor selling "tesamorelin" offers a legal product. Sources that disqualify themselves include:

• Vendors selling without requiring a prescription. Tesamorelin is Rx-only under federal law. Any sale without a valid prescription violates the FD&C Act.
• "Research chemical" suppliers marketing tesamorelin as a peptide "for laboratory use only." Because tesamorelin is an FDA-approved drug, this framing does not create a legal loophole; it is misbranding under 21 U.S.C. § 331.
• 503B outsourcing facilities compounding tesamorelin at scale without a patient-specific prescription. A 503B facility may compound copies of an FDA-approved drug only during declared shortage conditions or under specific FDA guidance. No active shortage listing for Egrifta SV was in effect as of early 2025. [9]
• Foreign online pharmacies shipping tesamorelin to Maryland addresses without FDA import clearance. Importation of prescription drugs from outside the U.S. For personal use is technically prohibited under current FDA policy for most drugs; tesamorelin has no personal importation exemption. [12]

Insurance Coverage and Cost in Maryland

Private Insurance

Most commercial plans in Maryland require prior authorization for Egrifta SV. The prescriber must document HIV-associated lipodystrophy confirmed by imaging (typically CT or DEXA), a qualifying CD4/viral-load history, and failure of less costly interventions. Approval timelines range from 3 to 14 business days.

Maryland Medicaid (HealthChoice)

HIV-positive Maryland Medicaid beneficiaries have the strongest formulary access. The state participates in the AIDS Drug Assistance Program (ADAP), and Egrifta SV has been on the Maryland ADAP formulary. Patients should contact their case manager or the Maryland ADAP program directly for current formulary status.

Out-of-Pocket Compounded Tesamorelin

For patients accessing tesamorelin off-label through a 503A compounder, insurance rarely covers costs. Monthly out-of-pocket costs at compounding pharmacies range from approximately $150 to $400 for a 2 mg/day protocol, making this pathway far more affordable than brand-name Egrifta SV for cash-pay patients.

HealthRX Clinical Decision Framework for Maryland Patients

The following framework is used by the HealthRX medical team when evaluating Maryland patients requesting tesamorelin access:

Step 1. Confirm indication and contraindications. Obtain HIV status, lipodystrophy imaging or clinical documentation, baseline IGF-1 (target: within age-adjusted reference range), fasting glucose, and HbA1c. Screen for active malignancy and pituitary pathology.

Step 2. Determine regulatory pathway. HIV-positive patient with documented lipodystrophy: brand Egrifta SV via specialty pharmacy, pursue insurance prior authorization. Off-label metabolic indication: 503A compounded tesamorelin via Maryland-licensed compounding pharmacy, cash pay or HSA.

Step 3. Prescriber licensure check. Confirm the ordering clinician holds an active Maryland license. Telehealth platforms must verify licensure before intake.

Step 4. Pharmacy compliance check. Confirm the dispensing pharmacy holds a Maryland Board of Pharmacy permit and, for compounders, current USP 797 compliance certification.

Step 5. Monitoring schedule. Recheck IGF-1 and fasting glucose at 12 weeks. Assess VAT reduction clinically or by imaging at 26 weeks. If no measurable response by 26 weeks, reconsider continuation.

Frequently Asked Questions